{'fraction_non_alphanumeric': 0.0416156670746634, 'fraction_numerical': 0.025703794369645042, 'mean_word_length': 4.76056338028169, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prevalence of GBV C/HGV RNA and GBV C/HGV Antibodies in French Volunteer Blood Donors: Results of a Collaborative Study

Background and Objectives: Posttransfusion hepatitis still occurs at an incidence of about 1 in 118,000 for HBV and 1 in 220,000 for HCV. This collaborative study aimed to determine the prevalence of a novel flavivirus, GBV–C/HGV, even though its role in transfusion–associated hepatitis is uncertain. Materials and Methods: GBV–C/HGV RNA was detected by PCR using either the Boehringer detection kit or by primers previously described. HGV antibodies were detected by a serological assay from Boehringer. Results: The observed GBV–C/HGV RNA frequency was 3.4%. HGV antibodies occurred in 9.5% of donors. Conclusion: In our study, 12.9% of the donors had been in contact with the GBV–C/HGV virus.